497 related articles for article (PubMed ID: 30002444)
1. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?
van Staalduinen J; Baker D; Ten Dijke P; van Dam H
Oncogene; 2018 Nov; 37(48):6195-6211. PubMed ID: 30002444
[TBL] [Abstract][Full Text] [Related]
2. The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance.
Seo J; Ha J; Kang E; Cho S
Arch Pharm Res; 2021 Mar; 44(3):281-292. PubMed ID: 33768509
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT).
Cho ES; Kang HE; Kim NH; Yook JI
Arch Pharm Res; 2019 Jan; 42(1):14-24. PubMed ID: 30649699
[TBL] [Abstract][Full Text] [Related]
4. Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition.
Sha J; Bai Y; Ngo HX; Okui T; Kanno T
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208465
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
Sui H; Zhu L; Deng W; Li Q
Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
[TBL] [Abstract][Full Text] [Related]
6. Roles of epithelial-mesenchymal transition in cancer drug resistance.
Shang Y; Cai X; Fan D
Curr Cancer Drug Targets; 2013 Nov; 13(9):915-29. PubMed ID: 24168191
[TBL] [Abstract][Full Text] [Related]
7. Roles and epigenetic regulation of epithelial-mesenchymal transition and its transcription factors in cancer initiation and progression.
Lee JY; Kong G
Cell Mol Life Sci; 2016 Dec; 73(24):4643-4660. PubMed ID: 27460000
[TBL] [Abstract][Full Text] [Related]
8. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.
Huang RY; Chung VY; Thiery JP
Curr Drug Targets; 2012 Dec; 13(13):1649-53. PubMed ID: 23061545
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-to-mesenchymal transition transcription factors in cancer-associated fibroblasts.
Baulida J
Mol Oncol; 2017 Jul; 11(7):847-859. PubMed ID: 28544627
[TBL] [Abstract][Full Text] [Related]
10. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
11. Effects of the HIF-1α and NF-κB loop on epithelial-mesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells.
Cheng ZX; Wang DW; Liu T; Liu WX; Xia WB; Xu J; Zhang YH; Qu YK; Guo LQ; Ding L; Hou J; Zhong ZH
Oncol Rep; 2014 Apr; 31(4):1891-8. PubMed ID: 24535079
[TBL] [Abstract][Full Text] [Related]
12. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
Tulchinsky E; Demidov O; Kriajevska M; Barlev NA; Imyanitov E
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):29-39. PubMed ID: 30419315
[TBL] [Abstract][Full Text] [Related]
13. Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition.
Hussain Y; Cui JH; Khan H; Aschner M; Batiha GE; Jeandet P
Med Oncol; 2021 May; 38(6):66. PubMed ID: 33950369
[TBL] [Abstract][Full Text] [Related]
14. Targeting EMT in Cancer with Repurposed Metabolic Inhibitors.
Ramesh V; Brabletz T; Ceppi P
Trends Cancer; 2020 Nov; 6(11):942-950. PubMed ID: 32680650
[TBL] [Abstract][Full Text] [Related]
15. SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell.
Liu H; Gu Y; Yin J; Zheng G; Wang C; Zhang Z; Deng M; Liu J; Jia X; He Z
Cell Signal; 2014 Dec; 26(12):2710-20. PubMed ID: 25152373
[TBL] [Abstract][Full Text] [Related]
16. TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.
Santoro R; Carbone C; Piro G; Chiao PJ; Melisi D
Drug Resist Updat; 2017 Nov; 33-35():36-42. PubMed ID: 29145973
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer.
Inoue Y; Itoh Y; Sato K; Kawasaki F; Sumita C; Tanaka T; Morishita D; Hayashi H
Curr Cancer Drug Targets; 2016; 16(2):110-8. PubMed ID: 26560121
[TBL] [Abstract][Full Text] [Related]
18. The relationship between platinum drug resistance and epithelial-mesenchymal transition.
Brozovic A
Arch Toxicol; 2017 Feb; 91(2):605-619. PubMed ID: 28032148
[TBL] [Abstract][Full Text] [Related]
19. MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53.
Sun W; Tang L
Curr Med Chem; 2016; 23(40):4529-4539. PubMed ID: 27686656
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance.
Du F; Liu H; Lu Y; Zhao X; Fan D
Crit Rev Oncog; 2017; 22(3-4):275-282. PubMed ID: 29604904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
